Electronic Health Records: Is Blockchain a Good Fit?
Even though paper records for most medical practices have evolved to digital, all of that data currently resides in silos, where consumers attempt to reconcile data among their providers and health payors. This can be challenging, as there is no single source that identifies where all of an individual’s health data resides, let alone the order in which it was entered.
Researching cancer mortality over the past few months has proved to be a bit of an eye-opener, and in three ways: firstly the level of excess mortality seen in a number of cancers, secondly the duration over which an extra risk persists, and thirdly that excess mortality may extend over a considerable period.
This article will provide a contemporary perspective of HCM, including potential treatment modalities and how its risk is currently stratified. Aspects of this condition that present particular challenges for the insurance underwriter will also be described.
Digitization in the Insurance Industry - Opportunities for the Application Process
Digitization has spread to every aspect of our personal and professional lives - including, of course, the insurance industry. It affects all sorts of different areas: from interfaces with end-customers and brokers, to wearables like fitness trackers that are supposed to encourage customers to behave in a more self-aware way.
Generally we think of lymphoma as a blood cancer (like Hodgkins and non-Hodgkins disease)—diagnosable diseases from blood testing and lymph node involvement. Occasionally, the lymphomas may arise from primary skin disease.
It’s Time to Future-Proof Your Data, Systems and Culture
The long-term prospects of most Life and Health insurers are going to be determined by their ability to transition from a product-based approach to a customer-centric value proposition. But, if they’re going to make that leap, insurers will have to know more about their customers, their behaviors and decision-making processes.
Providing an excellent customer experience is more important than ever as a strategic differentiator for insurance companies. Here’s what it takes to provide a customer experience that leads to brand insistence.
Our paper, “Cystatin C: A Promising Test for Insurance Screening,” was published in early 2009. At that time, most studies about this test were focused solely on its role as a novel kidney disease marker.
In the interim, several hundred new studies have greatly expand- ed our knowledge about cystatin C in a broad range of contexts. For this reason, a new comprehensive literature review is needed if we are to understand the true underwriting implications of this test.
A presentation at a recent underwriting gathering was billed as being focused on the use of predictive analytics in contexts other than risk appraisal.
Feedback from several attendees suggests it was just the opposite, centered largely on their deployment in underwriting.
So much for the verisimilitude of at least some session descriptions!
Fact is, insurers are presently being inundated with risk screening options no one would have imagined possible a decade ago. The developers of some of these tools are aggressively promoting their deployment in the underwriting process.
Bilirubin is a potent antioxidant and antiinflammatory agent. While bilirubin levels tend to be lower in cigarette smokers, the adverse effects of low/below normal bilirubin impact both smokers and nonsmokers.
High normal/elevated bilirubin has been convincingly linked to a significantly lower risk of circulatory diseases, diabetes and other prevalent medical impairments. Conversely, low normal/below normal bilirubin levels are now a well-established marker for increased risk of these diseases and their complications.